Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes

Overview

Journal J Clin Med Res

Specialty General Medicine

Date 2022 Feb 25

PMID 35211212

Authors

Hernando Vargas-Uricoechea

Affiliations

Soon will be listed here.

Abstract

Treatment with basal insulins is a fundamental part of management in many patients with type 2 diabetes mellitus. Multiple management schemes may be indicated in these individuals, for example, the use of oral antihyperglycemic agents with basal insulins (basal-supported oral therapy) or the combinations of basal insulins with glucagon-like peptide-1 receptor agonists; each of these strategies makes it easier to achieve glycemic control goals. A basic knowledge of the physiology, pharmacodynamic and pharmacokinetic aspects of the different basal insulins is essential to achieve treatment goals and compliance. This review addresses the principles of management with basal insulins.

Citing Articles

Identifying the Relationship Between CGM Time in Range and Basal Insulin Adherence in People With Type 2 Diabetes.

Norlev J, Kronborg T, Jensen M, Vestergaard P, Hejlesen O, Hangaard S J Diabetes Sci Technol. 2024; :19322968241296828.

PMID: 39523580 PMC: 11571617. DOI: 10.1177/19322968241296828.

Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study.

Di Loreto C, Celleno R, Pezzuto D, Ambrosi F, Bellavita S, Biagini M Diabetes Ther. 2024; 15(6):1313-1331.

PMID: 38605275 PMC: 11096145. DOI: 10.1007/s13300-024-01564-z.

An introduction to insulin use in type 2 diabetes mellitus.

Coetzee A S Afr Fam Pract (2004). 2023; 65(1):e1-e5.

PMID: 37132569 PMC: 10157446. DOI: 10.4102/safp.v65i1.5702.

References

Marques R, Fontaine M, Rogers J . C-peptide: much more than a byproduct of insulin biosynthesis. Pancreas. 2004; 29(3):231-8. DOI: 10.1097/00006676-200410000-00009. View

Antoszewski A, Feng C, Vani B, Thiede E, Hong L, Weare J . Insulin Dissociates by Diverse Mechanisms of Coupled Unfolding and Unbinding. J Phys Chem B. 2020; 124(27):5571-5587. PMC: 7774804. DOI: 10.1021/acs.jpcb.0c03521. View

Lefebvre P, Scheen A . Glucose metabolism and the postprandial state. Eur J Clin Invest. 1999; 29 Suppl 2:1-6. DOI: 10.1046/j.1365-2362.1999.00003.x. View

Garber A, Handelsman Y, Grunberger G, Einhorn D, Abrahamson M, Barzilay J . CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - . Endocr Pract. 2020; 26(1):107-139. DOI: 10.4158/CS-2019-0472. View

Clements J, Threatt T, Ward E, Shealy K . Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. Clin Pharmacokinet. 2016; 56(5):449-458. DOI: 10.1007/s40262-016-0464-6. View

Zhuang Y, Peng H, Huang F . A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2013; 17(19):2566-70. View

Philis-Tsimikas A, Klonoff D, Khunti K, Bajaj H, Leiter L, Hansen M . Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia. 2020; 63(4):698-710. PMC: 7054369. DOI: 10.1007/s00125-019-05080-9. View

Khunti K, Giorgino F, Berard L, Mauricio D, Harris S . The importance of the initial period of basal insulin titration in people with diabetes. Diabetes Obes Metab. 2019; 22(5):722-733. PMC: 7187252. DOI: 10.1111/dom.13946. View

Cheng A, Patel D, Reid T, Wyne K . Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Adv Ther. 2019; 36(5):1018-1030. PMC: 6824364. DOI: 10.1007/s12325-019-00925-6. View

10.

Lisco G, De Tullio A, Guastamacchia E, Triggiani V . Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature. Endocr Metab Immune Disord Drug Targets. 2020; 21(4):626-646. DOI: 10.2174/1871530320666200705211224. View

11.

Owens D . Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opin Drug Metab Toxicol. 2016; 12(8):977-87. DOI: 10.1080/17425255.2016.1202916. View

12.

Cernea S, Raz I . Insulin Therapy: Future Perspectives. Am J Ther. 2019; 27(1):e121-e132. DOI: 10.1097/MJT.0000000000001076. View

13.

Thorens B . GLUT2, glucose sensing and glucose homeostasis. Diabetologia. 2014; 58(2):221-32. DOI: 10.1007/s00125-014-3451-1. View

14.

Wilson L, Castle J . Recent Advances in Insulin Therapy. Diabetes Technol Ther. 2020; 22(12):929-936. PMC: 7864088. DOI: 10.1089/dia.2020.0065. View

15.

Hatting M, Tavares C, Sharabi K, Rines A, Puigserver P . Insulin regulation of gluconeogenesis. Ann N Y Acad Sci. 2017; 1411(1):21-35. PMC: 5927596. DOI: 10.1111/nyas.13435. View

16.

Hong T, Lu J, Zhang P, Zhang Z, Xu Q, Li Y . Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Ther. 2019; 10(3):1051-1066. PMC: 6531585. DOI: 10.1007/s13300-019-0606-6. View

17.

Owens D, Traylor L, Mullins P, Landgraf W . Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract. 2017; 124:57-65. DOI: 10.1016/j.diabres.2016.10.022. View

18.

Smyth T . Understanding the principles of insulin use in type 1 and type 2 diabetes management. Nurs Stand. 2020; 36(1):61-66. DOI: 10.7748/ns.2020.e11677. View

19.

Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K . (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020; 11:CD005613. PMC: 8095010. DOI: 10.1002/14651858.CD005613.pub4. View

20.

Lucidi P, Porcellati F, Candeloro P, Cioli P, Marinelli Andreoli A, Marzotti S . Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study. Nutr Metab Cardiovasc Dis. 2014; 24(7):709-16. DOI: 10.1016/j.numecd.2014.02.008. View